Back to results
US 5,346,887 AGranted
Glaucoma treatment
AssigneeAbbott Laboratories
InventorsHerman H. Stein, Jacob J. Plattner, Steven R. Crowley
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAbbott Laboratories
InventorsHerman H. Stein, Jacob J. Plattner, Steven R. Crowley
Estimating the term…
A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: ##STR1## wherein A is a substituent; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 wherein R.sub.2 is hydrogen or loweralkyl; with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloalkylmethyl, benzyl, (alpha, alpha) -dimethylbenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, 1-benzyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino; R.sub.3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)loweralkyl, (thioalkoxy)alkyl, benzyl or heterocyclic ring substituted methyl; and R.sub.4 is substituted hydroxyalkylamino.
A method for treating glaucoma or reducing and/or controlling intraocular pressure comprising administering to a patient in need a therapeutically effective amount of the renin inhibiting compound H-((beta,beta-dimethyl)-beta-Ala)-(4-OCH.sub.3)Phe-His amide of 2(S)-amino-1-cyclohexyl-3(R),4(S)-dihydroxy-6-methylheptane, or a pharmaceutically acceptable salt or ester thereof in combination with a therapeutically effective amount of a steroidal antiinflammatory agent.
A method for treating glaucoma or reducing and/or controlling intraocular pressure comprising administering to a patient in need a therapeutically effective amount of the renin inhibiting compound H-((beta,beta-dimethyl)-beta-Ala)-(4-OCH.sub.3)Phe-His amide of 2(S)-amino-1-cyclohexyl-3(R),4(S)-dihydroxy-6-methylheptane, or a pharmaceutically acceptable salt or ester thereof in combination with a therapeutically effective amount of an angiotensin converting enzyme inhibiting compound.
A composition for treating glaucoma or reducing and/or controlling intraocular pressure comprising a pharmaceutical vehicle suitable for topical ocular administration and a therapeutically effective amount of the renin inhibiting compound H-((beta,beta-dimethyl)-beta-Ala)-(4-OCH.sub.3)Phe-His amide of 2(S)-amino-1-cyclohexyl-3(R),4(S)-dihydroxy-6-methylheptane, or a pharmaceutically acceptable salt or ester thereof in combination with a therapeutically effective amount of a steroidal antiinflammatory agent.
A composition for treating glaucoma or reducing and/or controlling intraocular pressure comprising a pharmaceutical vehicle suitable for topical ocular administration and a therapeutically effective amount of the renin inhibiting compound H-((beta,beta-dimethyl)-beta-Ala)-(4-OCH.sub.3)Phe-His amide of 2(S)-amino-1-cyclohexyl-3(R),4(S)-dihydroxy-6-methylheptane, or a pharmaceutically acceptable salt or ester thereof in combination with a therapeutically effective amount of an angiotensin converting enzyme inhibiting compound.
Dependencies are inferred from the claim text.